



HAL
open science

Therapeutic exon skipping for dysferlinopathies?

Annemieke Aartsma-Rus, Kavita Singh, Ivo Fokkema, Ieke Ginjaar, Gert-Jan Boudewijn van Ommen, Johan den Dunnen, Silvère van Der Maarel

► **To cite this version:**

Annemieke Aartsma-Rus, Kavita Singh, Ivo Fokkema, Ieke Ginjaar, Gert-Jan Boudewijn van Ommen, et al.. Therapeutic exon skipping for dysferlinopathies?. *European Journal of Human Genetics*, 2010, n/a (n/a), pp.n/a-n/a. 10.1038/ejhg.2010.4 . hal-00509049

HAL Id: hal-00509049

<https://hal.science/hal-00509049>

Submitted on 10 Aug 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Therapeutic exon skipping for dysferlinopathies?

Annemieke Aartsma-Rus, Kavita Singh, Ivo A.C. Fokkema, Ieke B. Ginjaar, Gert-Jan

van Ommen, Johan T. den Dunnen and Silvère M. van der Maarel

Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden,
the Netherlands

Corresponding Author: Annemieke Aartsma-Rus
Department of Human Genetics S4-P
Leiden University Medical Center
PO Box 9600
2300 RC Leiden
The Netherlands
Tel +31 715269436
Fax +31 715268285
Email: a.m.rus@lumc.nl

Short title: Exon skipping for dysferlinopathies?

Abstract

Antisense-mediated exon skipping is a promising therapeutic approach for Duchenne muscular dystrophy (DMD) currently tested in clinical trials. The aim is to reframe dystrophin transcripts using antisense oligonucleotides (AONs). These hide an exon from the splicing machinery to induce exon skipping, restoration of the reading frame and generation of internally deleted, but partially functional proteins. It thus relies on the characteristic of the dystrophin protein, which has essential N- and C- terminal domains, while the central rod domain is largely redundant.

This approach may also be applicable to Limb Girdle Muscular Dystrophy type 2B (LGMD2B), Myoshi Myopathy (MM) and distal myopathy with anterior tibial onset (DMAT), which are caused by mutations in the dysferlin-encoding *DYSF* gene.

Dysferlin has a function in repairing muscle membrane damage. Dysferlin contains calcium dependent C2 lipid binding (C2) domains and an essential transmembrane domain. However, mildly affected patients where one or a large number of *DYSF* exons were missing have been described, suggesting that internally deleted dysferlin proteins can be functional. Thus, exon skipping might also be applicable as a LGMD2B, MM and DMAT therapy.

We have here analyzed the dysferlin protein domains and *DYSF* mutations and describe which exons are promising targets with regard to applicability and feasibility.

We also show that *DYSF* exon skipping appears to be as straightforward as *DMD* exon skipping as AONs to induce efficient skipping of 4 *DYSF* exons were readily identified.

Keywords: Dysferlinopathy, antisense, exon skipping, therapy, splicing

Introduction

Limb-Girdle Muscular Dystrophy type 2B (LGMD2B), Myoshi Myopathy (MM) and distal myopathy with anterior tibial onset (DMAT) are autosomal recessive allelic muscle diseases caused by mutations in the dysferlin-encoding *DYSF* gene, leading to severely reduced or complete absence of the dysferlin protein¹⁻³. Most patients have small mutations: stop- or frame-shift mutations lead to prematurely truncated proteins, while missense mutations generally affect protein stability⁴. Over 100 different mutations have been reported in the Leiden Open Variation Database for almost 200 patients (www.dmd.nl). As there is currently no treatment for the “dysferlinopathies”, lack of dysferlin leads to progressive loss of tissue and function of the muscles of the limbs and girdle⁵.

The dysferlin protein is expressed in many tissues, but most abundantly in heart and skeletal muscle⁵. In the latter the protein is located at the plasma membrane and in cytoplasmic vesicles⁶. It is thought that dysferlin has a function in vesicle trafficking and membrane patch fusion repair in muscle cells⁵. Loss of dysferlin compromises skeletal muscle membrane repair and leads to progressive loss of muscle fibers⁶. The protein has different domains (Figure 1). The ENSEMBL database predicts 6 or 7 calcium-dependent C2 lipid-binding (C2) domains, a transmembrane domain and multiple “fer” and “dysf” domains. The C2 domains probably mediate calcium-dependent vesicle fusion with the plasma membrane, while the transmembrane domains anchors the protein to the plasma membrane⁵. The fer and dysf domains have as yet an unknown function⁴.

It is likely that parts of the dysferlin protein are redundant. The first indication for this is a finding by Sinreich and colleagues that the mother of two LGMD2B patients turned out to be a compound heterozygote rather than a carrier⁷. One of the

alleles contained a mutated branchpoint in intron 31, leading to skipping of exon 32. As exon 32 skipping does not disrupt the open reading frame, this resulted in a slightly shorter but apparently partly functional dysferlin protein at levels that were 10% of wild type levels. The patient had only very mild proximal muscle weakness, elevated serum creatine kinase levels and was still ambulant at age 70. By contrast, her severely affected daughters were homozygous for a null mutation and had no dysferlin protein. In addition, a mildly affected patient has been presented with a dysferlin containing only the final two C2 and the transmembrane domains⁸. This patient was ambulant without a cane at age 41. Further proof for the functionality of this protein came from its proper location at the sarcolemma and the delivery of a gene encoding this “minidysferlin” into a dysferlin-negative mouse model through an adeno-associated viral vector. This resulted in detectable levels of the mini-dysferlin protein and an improved phenotype.

Thus, it is possible that bypassing dysferlin mutations could lead to more stable, (partly) functional dysferlin proteins and would therefore have therapeutic potential. A way to achieve this is the modulation of dysferlin pre-mRNA splicing using antisense oligonucleotides (AONs) or antisense sequences, which hide target exons from the splicing machinery, such that they are not included into the final mRNA (“exon skipping”) (Figure 2). Initial proof of concept was recently shown in control and patient-derived cells, where exon 32 skipping was induced by either AONs or through an a modified U7 snRNP where the original antisense sequence was replaced by the target antisense sequence⁹.

In fact, the exon skipping approach is currently the most promising therapeutic approach for Duchenne muscular dystrophy (DMD)¹⁰. This disease is caused by a

complete loss of functional dystrophin due to mutations that disrupt the open reading frame of the *DMD* gene¹¹. Like dysferlin, dystrophin contains essential and less essential domains, underlined by the finding that patients with in-frame mutations in the redundant central domain suffer from a milder disease called Becker muscular dystrophy¹²⁻¹⁴. AON-mediated exon skipping for DMD patients aims to restore the open reading frame, to allow the production of a partly functional protein and conversion of the severe DMD into a milder BMD phenotype. This approach was pioneered in our lab and by colleagues in Japan, Australia and the UK^{10,15-18} and is currently in phase I/II clinical trials^{19,20}.

Here, we will analyze which *DYSF* exons might be suitable targets for antisense-mediated exon skipping and which are less or non suitable targets, based on the protein encoding domains and reported mutations. We also show that using our guidelines established after retrospective analysis of our set of *DMD* AONs, AONs to induce *DYSF* exon skipping can be readily identified.

Methods

Database

Mutations as reported on May 8th 2009 in the *DYSF* LOVD database (www.dmd.nl) were analyzed.

AONs

AON design was based on our guidelines for *DMD* exons and focused on targeting partially open secondary RNA structures (predicated by m-fold²¹), the presence of predicted RESCUE-ESE and SC35 and the absence of predicted Tra2 β sites (using the human splicing finder²²) and favorable binding energy^{21,23}. All AONs (Table 1)

target exon-internal sequences and consist of 2'-O-methyl RNA with a full length phosphorothioate backbone and were manufactured by Eurogentec (Belgium).

Cell culture and transfection

Human control myoblasts were cultured and differentiated as described previously²⁴. AONs were transfected at a 500 nM concentration using 2.5 µl polyethyleneimine (MBI-Fermentas) per µg AON, following manufacturer's instructions. An unrelated 5-fluorescein labeled AON targeting exon 45 of the dystrophin gene was used to confirm the efficiency of transfection (>90%).

RNA analysis

RNA was isolated >28 hours after transfection using RNA-Bee (Campro Scientific) according to the manufacturer's instruction. An RT-PCR was performed with random hexamer primers, as described²⁵. Primers flanking the targeted exons (sequence on request) were used to amplify the cDNA as described previously for dystrophin²⁴, but using a single PCR for 35 cycles. Skip products were analyzed by sequencing analysis as described²⁴.

Results and Discussion

Exon skipping for dysferlin

Obviously, not every *DYSF* exon can be skipped without consequence for dysferlin function. First, if the skipped exon is out-of-frame (i.e. the length is not divisible by 3), this will result in a disruption of the open reading frame and a prematurely truncated protein. Thus, either in-frame exons or a combination of out-of-frame exons that together maintain the reading frame, are valid targets (Figure 3, Table 2).

Secondly, as mentioned, dysferlin contains several domains; and while only limited information is available about their function and essentiality, several things can be learned about these domains from mutations found in patients and animal

models. The very mildly affected individual skipping exon 32 suggests that, although exon 32 encodes the fourth C2 domain, a dysferlin without this exon is highly functional⁷. Thus, apparently the fourth C2 domain is (at least partially) redundant. By contrast, the final C2 domain is likely essential for functionality, since a mouse model SJL/J (*SJL-Dysf*) with a splice site mutation resulting in the in-frame skipping of exon 45, leading to the omission of the last part of the final C2 domain has a dystrophic phenotype^{26,27}. The mild patient producing a dysferlin consisting of only the last C2 and the transmembrane domains could suggest that the other 4 C2 domains are redundant. However, whereas this corresponding mini-dysferlin protein is apparently relatively stable, this does not necessarily hold for all dysferlins with mutations before exon 44, and seems to be exception rather than rule⁴.

Thirdly, only internal exons can be skipped, thus exon 1 and exon 55 are invalid targets. Additional exons that provide invalid targets are in-frame exons 19, 25 and 49 for which splice site mutations resulting in exon skipping (confirmed by RT-PCR) have been found in LGMD2B and MM patients (⁴ and the LOVD DYSF database). Mutations that may affect splicing (i.e. located at or close to the splice sites) have been identified in MM and LGMD2B patients for exons 24, 30, 32, 34, 37 and 41. However, the mutations were found on DNA level and have not been confirmed on RNA level.

Based on this information, exons can be subdivided into suitable and less suitable and impossible candidates (Table 2). Even though there are no real mutational hotspots in the *DYSF* gene, some exons contain more mutations than others and the skipping of these exons would thus be applicable to larger groups of patients (see Table 2). Notably, no mutations have been thus far reported for exon 17 and exon 35.

Prioritizing DYSF exons

Obviously, when assessing the feasibility of *DYSF* exon skipping, one should start with the most straightforward approach (single exon skipping), targeting those exons that are most likely or have been confirmed to be redundant. This includes exons 17, 32, 35, 36 and 42. Since no mutations have been reported yet for exon 17 and 35, initial focus should not be on those exons. Exons 34 and 41 are in-frame and theoretically eligible targets as they encode no domains or the redundant C2 domain. However, putatively causal mutations that induce skipping of these exons have been identified on DNA level. Thus, exons 32 and 36 seem to be prime candidates, with the other mentioned exons close seconds.

As skipping two or three exons simultaneously (double and triple exon skipping, respectively) is feasible for *DMD*^{25,28}, it is probably also feasible for *DYSF*. The only combination of adjacent exons that together is in-frame (i.e. the total number of nucleotides is divisible by 3), while not encoding any domains is 20+21, while there are also some in-frame three exon combinations possible (18+19+20 and 31+32+33).

Finally, in-frame exons 24 and 30 encode the FerB and Dysf-C2 domains, additional domains for which the essentiality for dysferlin function is still unknown. Thus, exon skipping for these exons might be beneficial. All other exons or exon combinations encode C2 domains or the transmembrane domain and are very likely to interfere with protein function, and should have a lower priority (Table 2).

Skipping the highest priority exons (rank 1-3) could be beneficial for over 20% of all dysferlinopathy patients (Table 2). This is probably a slight overestimation, since a number of patients may be counted twice since they have mutations in two

4

1.1b

2.1

eligible exons (compound heterozygotes). The recessive nature of dysferlinopathies poses certain obstacles that are not present in the X-recessive DMD. For instance, a patient can have mutations in exon 32 and exon 30. When targeting both exons, it is likely that in most transcripts both exons will be skipped, as double exon skipping is usually quite efficient²⁵. This is probably not beneficial. However, levels of ~10% are apparently sufficient to prevent disease in the aforementioned patient who lacked exon 32⁷, suggesting that it is not essential to correct both mutations and/or restore dysferlin levels to 100%. Therefore it may be better to target just one mutated exon (e.g. exon 32), which will result in skipping of the unintended exon (wild type exon 32 in the exon 30 mutated transcript), but also of the intended exon (mutated exon 32). The intended exon skipping will result in functional dysferlin, while the unintended exon skipping will not further worsen the disease as a non-functional dysferlin (due to the exon 30 mutation) is now converted in another non-functional dysferlin (exon 30 mutation and exon 32 skip).

Feasibility of DYSF exon skipping

Antisense-mediated skipping of *DMD* exons is very straightforward; AONs to skip each exon have been identified^{23,29,30}. To assess whether exon skipping can be as easily achieved for *DYSF* exons, we designed 2 AONs for each exon targeting *DYSF* exons 19, 24, 30 and 34, and a single AON targeting the small exon 32, using our previously identified AON design guidelines^{23,29}. AONs were transfected in differentiated human control myoblasts. RT-PCR analysis revealed that 6 AONs were effective and induced skipping of exons 19, 24, 30 and 34 (Figure 4). Exon skipping levels varied from 17% (exon 34) to 96% (exon 30). Notably, some spontaneous skipping (alternative splicing) of exon 30 was observed in non-treated cells at low

4

levels (10%). The single exon 32 AON was not effective (Figure 4), but exon 32 skipping can be induced by other AONs ⁹.

1.2

For some DMD exons skipping of additional adjacent exons was observed, either exclusively or in addition to skipping of the targeted exon only ²⁹. This is unwanted for dysferlinopathies as the skipping of a number of in-frame exons leads to non-functional dysferlins (Table 2). However, skipping of additional exons was not observed for the 4 dysferlin exons targeted here (data not shown). Furthermore, the skipping of multiple exons happens only occasionally for DMD exons and even when it occurs the amount of transcripts with a single skip often vastly exceeds the amount of transcripts where more exons are skipped consecutively.

Concluding remarks

In conclusion exon skipping poses a putative strategy for dysferlinopathies, though some exons are arguably more eligible than others. It should be pointed out that the ideal target mutations are homozygous mutations in an eligible target exon, as in this case skipping the targeted exons on both alleles could be therapeutic. However, since 10% of dysferlin levels appear to be sufficient to improve the phenotype ⁷, this approach is also promising for heterozygous mutations. Here, only skipping of the mutated exon could be potentially therapeutic, while skipping of the non-target allele is not. Nevertheless, this could still lead to dysferlin levels of up to 50%. Fortunately, skipping *DYSF* exons appears to be straightforward. It is known that some mutations can cause misfolding of dysferlin and retention in the endoplasmatic reticulum ³¹. This is a possibility for the internally deleted dysferlins as well. Therefore, studies in patient-derived cells are needed, as only these will be able to confirm whether other internally deleted dysferlins are functional and located properly.

Acknowledgements

AAR is funded by grants from ZonMw (the Netherlands) and the Duchenne Parent Project (the Netherlands) and the FP6 TREAT-NMD network of excellence.

Conflict of interest statement:

AA-R and G-JBvO are employees of Leiden University Medical Center and coinventors on patent applications for antisense sequences and exon-skipping technology.

Reference List

- 1 Liu J, Aoki M, Illa I *et al*: Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. *Nat Genet* 1998; **20**: 31-36.
- 2 Bashir R, Britton S, Strachan T *et al*: A gene related to *Caenorhabditis elegans* spermatogenesis factor *fer-1* is mutated in limb-girdle muscular dystrophy type 2B. *Nat Genet* 1998; **20**: 37-42.
- 3 Illa I, Serrano-Munuera C, Gallardo E *et al*: Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. *Ann Neurol* 2001; **49**: 130-134.
- 4 Therrien C, Dodig D, Karpati G, Sinnreich M: Mutation impact on dysferlin inferred from database analysis and computer-based structural predictions. *J Neurol Sci* 2006; **250**: 71-78.
- 5 Bansal D, Campbell KP: Dysferlin and the plasma membrane repair in muscular dystrophy. *Trends Cell Biol* 2004; **14**: 206-213.
- 6 Bansal D, Miyake K, Vogel SS *et al*: Defective membrane repair in dysferlin-deficient muscular dystrophy. *Nature* 2003; **423**: 168-172.
- 7 Sinnreich M, Therrien C, Karpati G: Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy. *Neurology* 2006; **66**: 1114-1116.
- 8 Krahn M, Wein N, Lostal W *et al*: Partial functionality of a Mini-dysferlin molecule identified in a patient affected with moderately severe primary dysferlinopathy. *Neuromuscul Disord* 2008; **18**: 781.

- 9 Wein N, Avril A, Bartoli M *et al*: Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. *Hum Mutat* 2009.
- 10 van Ommen GJ, van Deutekom J, Aartsma-Rus A: The therapeutic potential of antisense-mediated exon skipping. *Curr Opin Mol Ther* 2008; **10**: 140-149.
- 11 Hoffman EP, Brown RH, Jr., Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell* 1987; **51**: 919-28.
- 12 Hoffman EP, Fischbeck KH, Brown RH *et al*: Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. *N Engl J Med* 1988; **318**: 1363-8.
- 13 Koenig M, Monaco AP, Kunkel LM: The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. *Cell* 1988; **53**: 219-26.
- 14 Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM: An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. *Genomics* 1988; **2**: 90-5.
- 15 Dunkley MG, Manoharan M, Villiet P, Eperon IC, Dickson G: Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. *Hum Mol Genet* 1998; **7**: 1083-90.
- 16 Takeshima Y, Wada H, Yagi M *et al*: Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. *Brain Dev* 2001; **23**: 788-90.
- 17 Wilton SD, Lloyd F, Carville K *et al*: Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. *Neuromuscul Disord* 1999; **9**: 330-8.
- 18 van Deutekom JC, Bremmer-Bout M, Janson AA *et al*: Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. *Hum Mol Genet* 2001; **10**: 1547-54.
- 19 Muntoni F, Bushby KD, van Ommen G: 149th ENMC International Workshop and 1st TREAT-NMD Workshop on: "planning phase i/ii clinical trials using systemically delivered antisense oligonucleotides in duchenne muscular dystrophy". *Neuromuscul Disord* 2008; **18**: 268-275.
- 20 van Deutekom JC, Janson AA, Ginjaar IB *et al*: Local dystrophin restoration with antisense oligonucleotide PRO051. *N Engl J Med* 2007; **357**: 2677-2686.
- 21 Zuker M: Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res* 2003; **31**: 3406-3415.
- 22 Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C: Human Splicing Finder: an online bioinformatics tool to predict splicing signals. *Nucleic Acids Res* 2009; **37**: e67.

- 23 Aartsma-Rus A, van Vliet L, Hirschi M *et al*: Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms. *Mol Ther* 2008.
- 24 Aartsma-Rus A, Janson AA, Kaman WE *et al*: Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. *Hum Mol Genet* 2003; **12**: 907-14.
- 25 Aartsma-Rus A, Janson AA, Kaman WE *et al*: Antisense-induced multiexon skipping for duchenne muscular dystrophy makes more sense. *Am J Hum Genet* 2004; **74**: 83-92.
- 26 Vafiadaki E, Reis A, Keers S *et al*: Cloning of the mouse dysferlin gene and genomic characterization of the SJL-Dysf mutation. *Neuroreport* 2001; **12**: 625-629.
- 27 Bittner RE, Anderson LV, Burkhardt E *et al*: Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. *Nat Genet* 1999; **23**: 141-142.
- 28 Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC: Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. *BMC Med Genet* 2007; **8**: 43.
- 29 Aartsma-Rus A, Winter CL, Janson AAM *et al*: Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. *Oligonucleotides* 2005; **15**: 284-297.
- 30 Wilton SD, Fall AM, Harding PL, McClorey G, Coleman C, Fletcher S: Antisense Oligonucleotide-induced Exon Skipping Across the Human Dystrophin Gene Transcript. *Mol Ther* 2007; **15**: 1288-1296.
- 31 Fujita E, Kouroku Y, Isoai A *et al*: Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). *Hum Mol Genet* 2007; **16**: 618-629.

Tables

See separate documents (Table 1 and Table 2)

Legends to Figures


Figure 1. Dysferlin domains relative to DYSF exons. Dysferlin contains 6 or 7 calcium dependent C2 lipid binding domains (C2), a transmembrane domain (T), a ferl domain (L), FerA and FerB domains (A and ,B respectively) and Dysf_N and Dysf_C domains (N and C, respectively). The C2 and transmembrane domains have a function in membrane repair. The function of other domains is yet unknown.



Figure 2. Antisense-mediated exon skipping. Left panel: In this example a mutation within exon 32 results in a premature stop codon (indicated by the transition of black to white in the pre-mRNA (top) and mRNA (middle), which leads to a prematurely truncated protein (bottom). Right panel: when antisense oligonucleotides (AON) targeting exon 32 are used, they will hybridize to this exon, thus hiding it from the splicing machinery, resulting in the skipping of this exon. Since exon 32 is in-frame (its length is divisible by 3), skipping will not disrupt the reading frame (the mRNA becomes black in the middle panel) and a full length protein, that misses a little bit in the middle, can be generated (bottom).


Figure 3. Dysferlin exons. In-frame exons are depicted in white, out-of-frame exons in black. Exons or combinations of exons can be skipped without disrupting the reading frame, when the resulting ends fit (e.g. exons 39 and 40 can be skipped, since the end of exon 38 fits to the beginning of exon 41).

Figure 4. RT-PCR analysis of AON-treated control cell cultures. AONs 19-2, 24-1, 24-2, 30-1, 30-2 and 34-1 are effective, while 19-1, 32, 34-2 and C (a control AON targeting the DMD (dystrophin) gene) are not. Correct exon skipping was confirmed

by sequence analysis (data not shown). No exon 19, 24, 32 or 34 skipping could be observed in non treated (NT) cells, while for exon 30 low levels of physiological skipping were observed. AON treatment significantly increased these levels from <10% to >90%. Skipping percentages (assessed with Agilent Lab on a Chip) are indicated below each skip. Note that the intensity of the skip products is lower, due to the smaller fragment length (our efficiency assessment corrects for this). -RT and H₂O are negative controls. M is size marker.














Table 1. AONs used in this study

AON name	Sequence	Exon
H19DYSF1	GAA GCC GGC CAC GAU AAG CC	19
H19DYSF2	CCU UCU GUU CAC UGU GCU CC	19
H24DYSF1	GCA UCC AGA UGA CGA UGU CCG	24
H24DYSF2	GCU UCC CAC AAU UCU UGC CA	24
H30DYSF1	CCG UCU UCU CCA GUG GCU CC	30
H30DYSF2	CGG CGG AAG GCA UCU GUC UUG	30
H32DYS1	UCC GUU CCA GAC UCG GUU CAC	32
H34DYSF1	CGA CGG CUG GCU GCC CCU CGU C	34
H34DYSF2	GCA GCG UAG AUG GUA GCG GU	34

Table 2. Properties of dysferlin exons

Exon	Domain	In frame	Combination ¹	Remarks	Applicability ²	Priority ³
1	C2-1	no	no		0%	NA
2	C2-1	no	2, 3, 4 and 5		1.8%	9
3	C2-1	no	3 and 4		2.1%	8
4	C2-1	no	3 and 4		1.3%	8
5	C2-1	no	5 and 6		4.2%	8
6	None	no	5 and 6		6.1%	8
7	C2-2	yes			1.6%	7
8	C2-2	yes			2.9%	7
9	C2-2	yes			1.8%	7
10	C2-2 & FerL	no	10 and 11		1.6%	8
11	C2-2 & FerL	no	10 and 11		0.5%	8
12	C2-3	no	12 and 13		16.6%	8
13	C2-3	no	12 and 13		4.5%	8
14	C2-3	no	14, 15 and 16		0.3%	9
15	C2-3	no	14, 15 and 16		2.6%	9
16	C2-3	no	14, 15 and 16		1.1%	9
17	C2-3	yes		No mutations reported Alternatively spliced	0%	1
18	none	no	18, 19 and 20		4.0%	3
19	none	yes		Skip pathogenic	5.8%	NA
20	none	no	20 and 21		5.3%	2

21	none	no	20 and 21		1.8%	2
22	FerA	no	22 and 23		0.8%	6
23	FerA & FerB	no	22 and 23		3.2%	6
24	FerB	yes		Skip possibly pathogenic	4.5%	5
25	FerB	yes		Skip pathogenic	3.7%	NA
26	Dysf-N-1	no	26 and 27		1.8%	6
27	Dysf-N-2	no	26 and 27		6.6%	6
28	Dysf-N-2	no	28 and 29		5.3%	6
29	Dysf-C-1	no	28 and 29		6.6%	6
30	Dysf-C-2	yes		Skip possibly pathogenic	8.4%	5
31	None	31, 32, 33	no		3.7%	3
32	C2-4	yes		Skip does not disturb function	4.0%	1
33	C2-4	31, 32, 33	no		2.4%	3
34	C2-4	yes		Skip possibly pathogenic	4.5%	4
35	None	yes		No mutations reported	0%	1
36	None	yes			0.8%	1
37	C2-5	yes		Skip possibly pathogenic	3.7%	7
38	C2-5	yes			3.7%	7
39	C2-5	no	39 and 40		3.2%	8
40	none	no	39 and 40		0.3%	8
41	none	yes		Skip possibly pathogenic	3.4%	4
42	none	yes			0.8%	1
43	C2-6	yes			4.2%	7
44	C2-6	no	44, 45, 46 and 47		11.9%	9

45	C2-6	yes		Skip pathogenic in mouse	5.3%	NA
46	none	no	46, 47 and 48		2.4%	9
47	none	no	46, 47 and 48		2.1%	9
48	C2-7	no	46, 47 and 48		1.1%	9
49	C2-7	yes		Skip pathogenic	4.7%	NA
50	C2-7	no	50, 51, 52 and 53		3.7%	9
51	C2-7	no	51 and 52		5.8%	8
52	C2-7	no	51 and 52		3.7%	8
53	none	no	53 and 54		5.0%	8
54	TMB	no	53 and 54		3.4%	8
55	TMB	no	not applicable		1.6%	NA

¹Indicates which combination of exons would be in-frame

²The applicability is based on the mutations reported in the DYSF database (www.dmd.nl). As most patients have heterozygous mutations, the total applicability is >100%.

³Indicates which exons make good targets on a scale of 1-9, where 1 is optimal and 9 least optimal, NA is for unsuitable exons,